NSE: DRREDDY · 21 October 2026
- Dr. Reddy's Laboratories shares are trading higher by 0.22% at ₹1,245.20, moving within a day's range of ₹1,239.00 and ₹1,250.50.
- The United States Food and Drug Administration completed a Pre-Approval Inspection at the FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, which was conducted between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated that it will address these observations within the stipulated timeframe.
- Trading volume was 0.20 times the 20-day average daily volume.
Why is Dr. Reddy S Laboratories share price rising on 21 October 2026?
Dr. Reddy's Laboratories shares are trading higher by 0.22% at ₹1,245.20, moving within a day's range of ₹1,239.00 and ₹1,250.50.
The broader market benchmark Nifty gained 0.36%, whereas the sector benchmark Nifty Pharma declined by 0.35%, reflecting mixed sector dynamics. The stock's modest gain sits against a positive 5-day return of 0.42% and a 20-day return of 3.91%.
On the corporate front, the company announced on October 21, 2026, that it received Central Drugs Standard Control Organisation (CDSCO) approval under the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. This regulatory milestone expands the therapeutic application of Zytorvi beyond its initial approval in nasopharyngeal carcinoma, providing an additional treatment option in the Indian oncology segment.
4.40 lakh shares traded by 21 October 2026 · 11:00 AM IST. This compares with a 20-day average daily volume of 21.92 lakh shares (0.20 times). The five-day average daily volume was 15.42 lakh shares. Separately, the NSE report for 19 October 2026 showed 4.89 lakh shares delivered, representing 47.76% of that day’s traded volume. The same report recorded 32,415 trades.
The modest gain of 0.22% coincides with the company's official announcement of receiving DCGI approval for Zytorvi in advanced esophageal squamous cell carcinoma, alongside elevated trading volumes relative to its 20-day average.
Latest Company Developments
The United States Food and Drug Administration completed a Pre-Approval Inspection at the FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, which was conducted between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated that it will address these observations within the stipulated timeframe.
Regulatory observations require timely remediation to ensure compliance and avoid potential delays in future product approvals tied to the facility.
The company issued an intimation confirming that its Board of Directors will meet on Friday, October 23, 2026, to approve and release the unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2026. Management has scheduled an earnings conference call at 19:30 PM IST on the same day to discuss the financial performance.
It sets the reporting timeline for investors to evaluate quarterly revenue growth, profit margins, and operational updates across core segments.
a press release dated October 07, 2026, titled "Intimation of Earnings call".
imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.
The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.16% on 30 June 2026. This compares with 13.19% on 31 March 2026, a change of -0.03 percentage points.
The filing reported 40 MF/UTI holders.
What to Watch Next
- Release of Q2FY27 financial results and management commentary scheduled for October 23, 2026
- Company response and remediation timeline regarding the USFDA Form 483 observations at the Visakhapatnam facility
- Commercial rollout progress and market uptake of Zytorvi for esophageal squamous cell carcinoma in India
- Delivery percentage trends relative to the recent 47.76% level
Other Dated Coverage
- Dr. Reddy's Laboratories in Focus After USFDA Issues Form 483 | 15 October 2026 — 15 October 2026
- Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 2.71% | 13 October 2026 — 13 October 2026
- Dr. Reddy's Laboratories in Focus After Setting Q2FY27 Earnings Date | 8 October 2026 — 8 October 2026
More Dr. Reddy S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Dr. Reddy S Laboratories company news?
The United States Food and Drug Administration completed a Pre-Approval Inspection at the FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, which was conducted between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated that it will address these observations within the stipulated timeframe.
How strong was Dr. Reddy S Laboratories’s trading volume?
4.40 lakh shares traded, 0.20 times the 20-day average daily volume. The price and volume data are dated 21 October 2026 · 11:00 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.